Recent preclinical studies have shown promising results with the successful distribution of a new drug to the liver, peritoneum, and lung. At clinically relevant doses, there were measurable reductions in tumor burden. This provides hope for potential treatment options with significant impact on combatting cancer. These findings mark a significant breakthrough in the field of oncology research.